HPV primary screening with the cobas® HPV Test identifies more high grade disease than a Pap test alone and maintains screening efficiency
Leading US medical societies (ACOG, ASCCP, SGO)* now recommend HPV primary screening as an option for cervical cancer screening women ages 25 and older.
Dr. Lee Shulman on HPV Primary Screening (Professor in Ob/Gyn at Feinberg School of Medicine, Northwestern University, Chicago):
The ATHENA study, the largest US prospective registrational clinical study of its kind, evaluated the performance of the HPV primary screening algorithm with the cobas ® HPV Test in women ages 25 and older.
ATHENA data indicates that screening women starting at 25 years with the cobas® HPV Test will help reduce the incidence of high-grade cervical disease
Evidence supports hrHPV testing for primary screening of cervical cancer.4
The cobas® HPV Test offers an opportunity to meet both goals of screening—it provides pooled hrHPV results on the known 12 “high-risk” genotypes and individual results on the highest-risk genotypes HPV 16 and 18, identifying women with the highest likelihood of harboring high-grade disease, while following a triage strategy that protects women from unnecessary intervention.2
See ATHENA HPV trial data on the use of the cobas® HPV Test as a primary screen.
1. Saslow D, Solomon D. Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137:516-542.
2. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study [published online August 23, 2011]. Lancet Oncol. doi:10.1016/S1470-2045(11)70188- 7.
3. Herzog TJ, Monk BH. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007;197:566-571.
4. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection for high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomized controlled trial. Lancet Oncol. 2012; 13:78-88.
5. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
6. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventative Services Task Force. Ann Intern Med. 2011; 155:687-697.
7. Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Ob Gyn. 2012:In Press.